EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz‐containing regimen

Sara Bettonte iD, Mattia Berton iD, Felix Stader iD, Manuel Battegay iD, Catia Marzolini iD

British Journal of Clinical Pharmacology · 2023

DOI: 10.1111/bcp.15867 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Sara Bettonte und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerla…. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Intramuscular cabotegravir/rilpivirine (IM CAB/RPV) are metabolized by UGT1A1/CYP3A4. Efavirenz induces both enzymes; therefore, switching from an efavirenz‐containing regimen to IM CAB/RPV could possibly result in suboptimal levels. Due to their long dosing interval, clinical studies with IM CAB/RPV are challenging. We used physiologically based pharmacokinetics (PBPK) modelling to simulate the switch from efavirenz to IM CAB/RPV.

Methods

First, we developed the drug models and verified the performance of the PBPK model to predict the pharmacokinetics of IM cabotegravir, IM rilpivirine and efavirenz by comparing the simulations against observed clinical data. Second, we verified the ability of the model to predict the effect of residual induction with observed data for the switch from efavirenz to dolutegravir or rilpivirine. Finally, we generated a cohort of 100 virtual individuals (20–50 years, 50% female, 18.5–30 kg/m 2 ) to simulate IM CAB/RPV concentrations after discontinuing efavirenz in extensive and slow metabolizers of efavirenz.

Results

IM CAB concentrations were predicted to decrease by 11% (95% confidence interval 7–15%), 13% (6–21%) and 8% (0–18%) at day 1, 7 and 14 after efavirenz discontinuation. CAB concentrations were predicted to remain above the minimal efficacy threshold (i.e., 664 ng/mL) throughout the switch period both in extensive and slow metabolizers of efavirenz. Similarly, IM RPV concentrations were modestly decreased with the lowest reduction being 10% (6–14%) on day 7 post last efavirenz dose.

Conclusion

Our simulations indicate that switching from an efavirenz‐containing regimen to IM CAB/RPV does not put at risk of having a time window with suboptimal drug levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsHumansFemaleMaleRilpivirineAnti-Retroviral AgentsBenzoxazinesAlkynesCyclopropanesPyridonesDiketopiperazines

Stichwörter der Autor:innen

PBPK modelling, pharmacokineticsdrug-drug interactionefavirenzlong-acting cabotegravirlong-acting rilpivirine

Substanzen

RilpivirineAnti-Retroviral AgentsBenzoxazinesAnti-HIV AgentsefavirenzAlkynesCyclopropanescabotegravirPyridonesDiketopiperazines

Autor:innen und Institutionen

  • Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland.
  • Faculty of Medicine, University of Basel, Basel, Switzerland.
  • Certara UK Limited, Sheffield, UK.
  • Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.

ORCID-Profile: Sara Bettonte, Mattia Berton, Felix Stader, Manuel Battegay, Catia Marzolini

Förderung

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Bettonte, S., Berton, M., Stader, F., Battegay, M., & Marzolini, C. (2023). Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz‐containing regimen. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15867

Vancouver

Bettonte S, Berton M, Stader F, Battegay M, Marzolini C. Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz‐containing regimen. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15867

BibTeX
@article{Bettonte2023,
  author = {Bettonte, Sara and Berton, Mattia and Stader, Felix and Battegay, Manuel and Marzolini, Catia},
  title = {Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz‐containing regimen},
  journal = {British Journal of Clinical Pharmacology},
  year = {2023},
  doi = {10.1111/bcp.15867}
}
Kostenlos starten →